ClouDr Group (9955) H1 2024 earnings summary

Executive summary

• H1 2024 revenue rose 17.9% YoY to RMB2,124.8m; net loss narrowed 25.5% to RMB118.9m and adjusted net loss narrowed 44.1% to RMB32.9m.

• Online prescriptions reached 116.1m, up 43.9% YoY, with average daily prescriptions exceeding 640,000.

Financial highlights

• Gross profit fell 7.7% YoY to RMB437.0m as cost of sales rose 27.0% to RMB1,687.8m; gross margin declined to 20.6% from 26.3%.

• Operating loss narrowed 33.3% YoY to RMB102.9m; net loss narrowed 25.5% to RMB118.9m.

• Adjusted net loss, excluding share-based compensation and specified financing-related items, was RMB32.9m vs RMB58.9m; adjusted net loss margin improved to 1.5% from 3.3%.

• Sales and marketing expenses fell 15.7% to RMB383.6m, administrative expenses fell 18.3% to RMB120.6m, and R&D expenses rose to RMB41.8m from RMB40.4m.

Outlook and guidance

• Priorities include expanding hospital and pharmacy SaaS networks, developing P2M products, investing in medical AI, growing patient and doctor users, and pursuing partnerships and acquisitions.

• Plans include deeper hospital relationships and monetization through targeted marketing and P2M, alongside broader pharmacy services, products, network coverage and P2M sales.

• Management expects the business-model flywheel to support commercialization and chronic disease management growth across hospital and outpatient channels.